美国Cell Therapeutics  
Cell Therapeutic公司的arsenic trioxide(三氧化二砷)
美国FDA已批准Cell Therapeutic公司的癌症治疗剂三氧化二砷用于治疗脊髓发育不良症状(MDS)的罕见药品的指定。MDS也称为前期的白血病或“不完全燃烧”的白血病，MDS是骨髓不能正常起作用以及产生的血细胞不足。该公司最近为三氧化二砷治疗另一种罕见病复发的或难治的急性早幼粒细胞白血病申报了美国的新药申请书，它对这种适应症具有最快的跟踪状态，这种产品对治疗多发性骨髓瘤具有罕见的药品状态

Cell Therapeutics, Inc., is a biopharmaceutical company focused on developing and commercializing novel agents that improve the safety and efficacy of existing standard-of-care chemotherapies, and those with unique,new mechanisms to kill cancer cells. We use genomic
information to determine which tumors have the greatest chance of responding favorably to a specific drug candidate.
This has the potential to change the way anticancer drugs are developed, by allowing investigators to pick the right drug for the right patient.